• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lupron Depot - Ped (leuprolide acetate for depot suspension) Injection, powder for suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2010

Summary View

 

ADVERSE REACTIONS

Clinical Trials
  • In two studies of children with central precocious puberty, in 2% or more of the patients receiving the drug, the following adverse reactions were reported to have a possible or probable relationship to drug as ascribed by the treating physician...(all available treatment-related adverse reaction data from the ongoing Study)
Postmarketing
  • Convulsion